CHF: Major News and Trial Updates in CHF in 2023
A quick rundown of the key developments: Trials: STEP-HFpEF CASTLE-HTx HEART FID DAPA-MI Policy and Guidelines: ESC cardiomyopathy guidelines Inflation Reduction Act FDA approvals: dapa...
20 Joulu 20234min
Valvular HD: 2023 Structural Highlights
Focus on Valves: TAVI vs. SAVR: Long-term data showed mixed results. PARTNER 3 (Sapien 3 valve) benefits declined over time, while Evolut Low Risk (CoreValve, Evolut R/PRO) favoured TAVI. Experts ad...
15 Joulu 20234min
CVD: 2023 Major Updates in General Cardiology
Key Highlights: Lodoco is the first anti-inflammatory approved for reducing cardiovascular events in ASCVD patients. Bempedoic acid offers an alternative for high-risk patients who can't tolerate s...
10 Joulu 20234min
PAD: Peripheral Arterial Disease Updates from 2023
Key Points of Endovascular Procedures and Devices in 2023: FDA Actions: Lifted restrictions on paclitaxel-coated balloons and stents for PAD after updated data showed no increased mortality risk. A...
5 Joulu 20234min
Electrophysiology: Important EP Updates from 2023
Heart Rhythm 2023: Innovations in Ablation, Devices, and Conduction System Pacing. Catheter Ablation and LAAO Advance: CASTLE-HTx: Ablation for AF proved beneficial in patients with advanced heart f...
30 Marras 20235min
PCI: Complete PCI in ACS and multi-vessel CAD, a systematic review
Key Points: Multi-vessel coronary disease (MVD) in acute myocardial infarction (AMI) is still a difficult condition to manage. Complete revascularization improves outcomes for hemodynamically stabl...
19 Loka 20232min
Afib: FRAIL-AF Trial: Anticoagulation in Frail Older Patients with Afib
Key findings of the FRAIL-AF trial: * Switching from vitamin K antagonist (VKA) to non-vitamin K antagonist oral anticoagulant (NOAC) therapy was associated with an increased risk of major and clini...
11 Syys 20232min
CHF: Semaglutide in HFpEF across obesity classes (STEP-HFpEF trial)
Summary of the STEP-HFpEF trial 2023 published in Nature Medicine The STEP-HFpEF trial was a study of semaglutide in patients with obesity phenotype of heart failure and preserved ejection fraction ...
3 Syys 20233min
